focal adhesion kinase

Overview

Focal adhesion kinase (FAK), also known as PTK2, is a non-receptor protein tyrosine kinase that functions as a central signaling node at focal adhesions, where cells attach to the extracellular matrix through integrins. It integrates mechanical cues and adhesion-dependent signals to regulate cell migration, survival, proliferation, cytoskeletal remodeling, and mechanotransduction. Through autophosphorylation and downstream signaling, FAK helps coordinate pathways such as RhoA/ROCK, YAP/TAZ, MAPK, and other adhesion-linked cascades.

In biomedical research, FAK is widely studied as a mediator of tumor progression, invasion, therapy resistance, and tissue mechanobiology. Recent studies in the provided context also place FAK in cartilage homeostasis under cyclic tensile stress, in viscoelasticity-dependent cell adhesion and migration, and in cancer-associated signaling axes including ITGA5-FAK in liver cancer and c-Met/FAK-linked oncogenic signaling in lung cancer. Because of its position at the interface of adhesion and signaling, FAK is a frequent therapeutic target in oncology and regenerative medicine.

Focus of Latest Publications

Recent publications highlight FAK as a mechanosensitive signaling hub and a target in cancer-related and tissue-engineering contexts.

In a multi-omics study of cartilage, cyclic tensile stress was reported to restore chondrocyte homeostasis through integrin-FAK-RhoA/ROCK2 signaling. The key mechanistic finding was that FAK knockdown abolished the tensile-stress-induced upregulation of RhoA and ROCK2, supporting FAK as the essential mediator of this response. This places FAK upstream of cytoskeletal and contractility-related signaling in primary chondrocytes and underscores its role in mechanotransduction in cartilage.

A materials-focused study on synthetic hydrogels with programmable viscoelasticity showed that the signaling efficacy of FAK and associated YAP/TAZ pathways, both central regulators of focal adhesion formation and cell migration, could be tuned by substrate tissue-matching viscoelasticity. This work links FAK activity to the physical properties of the cellular microenvironment and to adhesion-dependent migration behavior, with relevance to engineered matrices and cell-matrix interactions.

In hepatocellular carcinoma, RPRD1A was reported to drive lenvatinib resistance via the ITGA5-FAK signaling axis. The study concluded that upregulated ITGA5 activates FAK signaling, which critically contributes to resistance. This positions FAK as part of an integrin-dependent pathway associated with reduced therapeutic response in liver cancer.

Several studies examined direct or indirect inhibition of FAK in cancer models. A structure-based discovery study identified the first inhibitor targeting the talin2-β-integrin interaction with potent in vivo antitumor activity in breast cancer models; the compound inhibited FAK phosphorylation at Y397 and Y576, indicating suppression of canonical FAK activation downstream of integrin engagement. In colorectal cancer, conferone was reported to reduce FAK and p-FAK (Tyr397) protein levels and to reverse epithelial-mesenchymal transition, suggesting that FAK inhibition may counteract invasive phenotypes and metabolic reprogramming, including glutamine metabolism.

In non-small cell lung cancer, a self-assembling aggregation-induced emission nanoprobe was used for targeted therapy and real-time imaging. Mechanistically, the nanoprobe downregulated c-Met and downstream signaling pathways including FAK, MAPK, RAF, and STAT, thereby disrupting multiple oncogenic cascades. This indicates that FAK can be part of broader receptor tyrosine kinase-driven signaling networks in lung cancer.

A separate in-silico study of Pinellia ternata phytochemicals in lung cancer identified PTK2, the gene encoding FAK, among the core targets overlapping with lung cancer pathological genes. Although this work was computational, it supports the recurring appearance of FAK as a candidate node in multi-target anticancer strategies alongside FGFR4, CDK2, JAK2, KDR, PAK4, and PDGFRA.

Across these studies, FAK emerges as a convergence point for integrin signaling, mechanobiology, and oncogenic pathways. It is implicated in cartilage mechanoregulation, substrate-dependent cell migration, and resistance or progression in liver, colorectal, breast, and lung cancer, making it a recurring target in both experimental and computational therapeutic development.

Key Publications

• Jun Cyclic tensile stress restores chondrocyte homeostasis via integrin-FAK-RhoA/ROCK2 signaling: A multi-omics study. (Biochemical and biophysical research communications, 2026, PMID 41935436): "Crucially, FAK knockdown abolished the TS-induced upregulation of RhoA and ROCK2, confirming FAK as the essential mediator."
• May Dictated cell adhesion and migration using microfluidic-controlled synthetic hydrogels exhibiting programmable viscoelasticities. (Journal of materials chemistry. B, 2026, PMID 42093414): "We demonstrate that the signaling efficacies of the FAK and associated YAP/TAZ pathways, central regulators of FA formation and cell migration, are tuned by substrate tissue-matching viscoelasticity."
• May RPRD1A drives lenvatinib resistance in hepatocellular carcinoma via the ITGA5-FAK signaling axis. (Molecular biomedicine, 2026, PMID 42171939): "Upregulated ITGA5 subsequently activates focal adhesion kinase (FAK) signaling, which critically drives lenvatinib resistance."
• May In-silico prediction of multi‑target mechanisms of Pinellia ternata phytochemicals in lung cancer: Evidence from a graph‑attention‑guided virtual screening and multi‑scale simulations. (PloS one, 2026, PMID 42149884): "the potential targets of Pinellia ternata highly overlap with lung cancer pathological genes, with FGFR4, CDK2, JAK2, KDR, PAK4, PTK2 and PDGFRA being the core."
• May Structure-Based Discovery of the First Inhibitor Targeting the Talin2-β-integrin Interaction with Potent In Vivo Antitumor Activity in Breast Cancer Models. (Journal of medicinal chemistry, 2026, PMID 42020994): "It inhibited FAK phosphorylation at Y397 and Y576, and displayed good cellular uptake and cytoplasmic localization."
• May Development of a self-assembling aggregation-induced emission nanoprobe for targeted therapy and real-time imaging in non-small cell lung cancer. (Journal of photochemistry and photobiology. B, Biology, 2026, PMID 41793940): "Mechanistically, AIEnp downregulated c-Met expression and its downstream signaling pathways, including FAK, MAPK, RAF, and STAT, thereby effectively disrupting multiple oncogenic cascades."
• May Inhibitory Activity of Conferone on FAK Activity and Glutamine Metabolism in Human Colorectal Cancer. (Journal of cellular and molecular medicine, 2026, PMID 42056844): "At 10 μM, conferone reduced FAK and p-FAK (Tyr397) protein levels, reversing the epithelial-mesenchymal transition."